ReviewFrontiers in oncology2026
The role of epigenetic modifications in hematological cancers.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigenetic regulation of gene expression entails DNA methylation and histone modifications, which orchestrate chromatin structure and transcriptional activity. Aberrant regulation of these mechanisms contributes to the development and progression of hematological cancers. Mutations in enzymes mediating DNA methylation and histone modification patterns reshape chromatin structure, influencing transcriptional profiles, thus promoting oncogenesis, clonal evolution and drug resistance. This review focuses on significant alterations in DNA methylation patterns, mutations and changes in expression of histone modifying enzymes and chromatin remodeling complexes described in leukemias, lymphomas and multiple myeloma. We summarize the most prominent changes in epigenetic mediators and their impact on transcriptional activity and oncogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.